Moneycontrol

#MCExclusive | Yet another deal in the booming pharma CRO/CDMO segment as Quadria Capital set to acquire a 15% stake in Encube Ethicals valuing it at $800mn; Multiples PE to get an exit, reports Ashwin Mohan.

https://www.moneycontrol.com/news/business/companies/quadria-capital-to-buy-15-stake-in-encube-ethicals-valuing-firm-at-800-million-multiples-pe-to-get-exit-7095731.html

#QuadriaCapital #RakeshJhunjhunwala #Pharma

Moneycontrol

Quadria Capital To Buy 15% Stake In Encube Ethicals Valuing Firm At $800 Million; Multiples PE To Get Exit

The promoters of Encube Ethicals will also sell part stake to raise primary capital. Renuka Ramnath-led Multiples PE picked up a 10 percent stake in the firm in 2016.

13.3K views04:33

Moneycontrol

#MCExclusive ⚡️ Gland Pharma has had a scorching run on the bourses since its record Rs 6,480 cr #IPO; now Ashwin Mohan reports #Mumbai based Macleod’s Pharmaceuticals is weighing the next big-bang listing in the #pharma sector

https://www.moneycontrol.com/news/business/ipo/post-gland-pharmas-record-listing-macleod-pharmaceuticals-weighing-next-big-bang-ipo-in-pharma-sector-7220551.html?utm_source=telegram&utm_medium=social

Moneycontrol

Post Gland Pharma’s Record Listing, Macleod Pharmaceuticals Weighing Next Big-Bang IPO In Pharma Sector

Dr Rajendra Agarwal along with his brothers Girdhari Lal Bawri and Bandwari Lal Bawri started Mumbai based Macleods Pharmacuticals in 1986 with an aim to produce anti –TB medicines.

14.1K views12:05

Moneycontrol

Pharmaceuticals have long been considered a defensive sector for investors during times of uncertainty. The sector did live up to those expectations.

Viswanath Pilla tells us what to expect in the second quarter at: https://www.moneycontrol.com/news/business/companies/pharma-rides-on-covid-second-wave-in-q1-us-generics-remain-a-concern-7361591.html?utm_source=telegram&utm_medium=social

#Pharma #COVID19 #EarningsWithMC #Q1

Moneycontrol

Pharma Rides On Covid Second Wave In Q1; US Generics Remain A Concern

Companies expect sales in the Covid-19 portfolio to moderate in the second quarter even as sales of drugs in other categories increase. In the US generic drugs market, it could be another weak quarter

8.5K views15:32

Moneycontrol

#Pharma: Glenmark today announced that it had found no new side effects in the post-marketing surveillance (PMS) study on Favipiravir in over 1,000 #COVID19 patients. Viswanath Pilla reports ⏬

https://www.moneycontrol.com/news/business/companies/no-new-side-effects-found-in-covid-19-antiviral-favipiravir-glenmark-7469011.html?utm_source=telegram&utm_medium=social

Moneycontrol

No New Side Effects Found In COVID-19 Antiviral Favipiravir: Glenmark

Glenmark said the time for fever resolution was four days while time for clinical cure was seven days.

6.1K views07:34

Moneycontrol

#Pharma: #Lupin has entered into a $248-million settlement agreement with the plaintiffs in an antitrust class-action #lawsuit against the company for the delayed launch of the anti-diabetic drug Glumetza generic in the US. Read ⏬

https://www.moneycontrol.com/news/business/companies/delayed-launch-of-glumetza-lupin-settles-case-for-248-million-7472811.html?utm_source=telegram&utm_medium=social

by Viswanath Pilla

Moneycontrol

Delayed launch of Glumetza: Lupin settles case for $248 million

The law suits in US courts alleged that the 2012 settlement of patent litigation regarding Glumetza delayed the availability of generic alternatives, causing consumers to pay higher prices for the drug.

6.9K views06:52

Moneycontrol

#ICYMI | Rakesh Juhunjhunwala needs no introduction and is well known for his uncanny ability to spot the opportunity well before the others. His investments where he made a killing are well documented.

Titan is one of his investments that was in the news very recently for the sharp rally it witnessed and made fortunes for its investors like Jhunjhunwala.

https://www.moneycontrol.com/news/business/stocks/rakesh-jhunjhunwala-reduces-stake-in-pharma-major-lupin-7579151.html

#shareholding #rakeshjhunjhunwala #Pharma #Lupin #Stocks

Moneycontrol

Rakesh Jhunjhunwala Reduces Stake In Pharma Major Lupin

Trendlyne is showing Jhunjhunwala’s holding in the company as ‘below 1%’ as of September 30, 2021.

9.9K views18:13

Moneycontrol

Have you checked out #MCMinis yet? 🤔

They are quick explainers or short insights on topics that matter! They fit into the screenshot of your phone. 📲 It is that easy — and fast! ⚡️

Start exploring: https://moneycontrol.com/news/mcminis

#MCPersonalFinance #Pharma #MutualFund

6.2K views14:26

Moneycontrol

#Budget2022WithMC: The government has decided to stop #Pharma companies from claiming the cost of various freebies and largesse offered to doctors as a business deduction from April 1

Read at 👇
https://www.moneycontrol.com/news/trends/health-trends/budget-2022-stops-pharma-companies-from-claiming-tax-cuts-on-freebies-to-doctors-8024681.html?utm_source=telegram&utm_medium=social

Moneycontrol

Budget 2022 stops pharma companies from claiming tax cuts on freebies to doctors

Despite a code by the Medical Council of India that prohibits gifts from pharma companies to doctors that came into effect over a decade back, the practice has continued as there is no law barring the firms from offering the largesse to doctors

4.8K views05:50

Moneycontrol

#MCOpinion: The #pandemic has turned into a godsend opportunity for #pharma giants. With #vaccines ruling the roost, the companies and the management hit a jackpot. But it all came with a costly tag.

Read more 👇
https://www.moneycontrol.com/news/opinion/moneycontrol-pro-panorama-vaccine-windfall-for-big-pharma-but-at-what-cost-8066211.html?utm_source=telegram&utm_medium=social

Moneycontrol

Moneycontrol Pro Panorama | Vaccine windfall for Big Pharma, but at what cost?

In today’s edition of Moneycontrol Pro Panorama: Monsoon and the market, Airtel dials it big, Vedanta makes a U-turn, LIC IPO, brands play with fire and more